Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of LY2922470 in Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2018
At a glance
- Drugs LY 2922470 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Eli Lilly
- 31 Aug 2018 Biomarkers information updated
- 28 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.